As promising protein kinase inhibitors against multiple types of malignancies, PPP, pacritinib, and SKLB610 showed various degrees of inhibitory effects towards human lung cancer cells (Supplementary Figure S4, Table 1). This evidence concerns the gene WEE1 and lung cancer.